Dr. Divya M. Gupta, MD
Hematology & Oncology (Hematology & Oncology Physician)
645 N Michigan Ave Ste 1006
Chicago, IL 60611
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 9
- In the NPI registry since
- 2017
- Medicare patients seen, 2024
- 212
Licensed in Illinois since 2023, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2017Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
IL license 036165555 (first issued 2023; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Northwestern Medicine Central Dupage Hospital Winfield, IL
- Northwestern Memorial Hospital Chicago, IL
- Northwestern Lake Forest Hospital Lake Forest, IL
- Palos Community Hospital Palos Heights, IL
Medical groups
- Northwestern Medical Faculty Foundation (4,503 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 212
- Services billed
- 58,213
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, dexamethasone sodium phosphate, 1 mg | 174 | 16 |
| Injection of additional new drug or substance into vein | 50 | 20 |
| Injection of drug or substance under skin or into muscle | 26 | 17 |
| Administration of chemotherapy into vein, 1 hour or less | 25 | 21 |
| Established patient office or other outpatient visit, 30-39 minutes | 23 | 13 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 14 | 12 |
| New patient office or other outpatient visit, 45-59 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Dexamethasone Other prescribers in Chicago, IL | 48 |
| Prochlorperazine Maleate Other prescribers in Chicago, IL | 37 |
| Oxycodone Hcl Other prescribers in Chicago, IL | 31 |
| Tagrisso (osimertinib mesylate) | 28 |
| Ondansetron Odt (ondansetron) Other prescribers in Chicago, IL | 19 |
| Triamcinolone Acetonide Other prescribers in Chicago, IL | 15 |
| Ondansetron Hcl Other prescribers in Chicago, IL | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $3,150 in total to this clinician.
| Takeda Pharmaceuticals U.S.A., Inc. | $3,150 |
|---|
| Consulting Fee | $3,150 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. Feb 19, 2025 | Consulting Fee ALUNBRIG · ONCOLOGY | $3,150 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $71,188 in research payments for these studies, mostly to the institutions running them.
- HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer
Daiichi Sankyo Inc. · Active, not recruiting · NCT04676477
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.